Role of High-sensitivity C-reactive Protein as a Marker of Inflammation in Pre-dialysis Patients of Chronic Renal Failure
|
|
- Basil Dean
- 5 years ago
- Views:
Transcription
1 ORIGINAL ARTICLE JIACM 2009; 10(1 & 2): Abstract Role of High-sensitivity C-reactive Protein as a Marker of Inflammation in Pre-dialysis Patients of Chronic Renal Failure N Nand*, HK Aggarwal**, RK Yadav***, A Gupta****, M Sharma***** Introduction: Chronic inflammation is a major contributor to increased mortality and morbidity in end-stage renal disease (ESRD). The odds of cardiovascular disease (CVD) have been found to be 1.7 times greater in these cases. High-sensitivity CRP (hs-crp) has been reported to be the most powerful clinical marker of malnutrition and it also interacts with the haematopoietic system at several levels resulting in reduced haemoglobin levels. The aim of the present study was to analyse the evolution of pre-dialysis population of chronic kidney disease according to their basal levels of hs-crp. Material and methods: Forty pre-dialysis adult patients of ESRD with creatinine clearance in the range of 4-20 ml/min were included. Patients were divided into two groups. Those with hs-crp < 6 mg/dl were placed in group I and with hs-crp > 6 mg/dl in group II. The patients were followed for 6 months. Results: 40% of cases had an elevated level of hs-crp (mean mg/dl). Response to erythropoietin was blunted and the incidence of cardiovascular events was increased in patients with high values of hs-crp. Haemoglobin, serum albumin and BMI (body mass index) were significantly higher in patients having low hs-crp (p < 0.001, p < 0.05). No patient with low hs-crp required dialysis, whereas 88.75% of patients in high hs-crp group required haemodialysis (p < 0.001). Conclusion: A substantial number of patients of ESRD had elevated levels of hs-crp which was associated with poor clinical outcome including low haemoglobin, hypo-responsiveness to erythropoietin therapy, poor nutritional status, low albumin levels, greatly increased risk of cardiovascular disease, and frequent and early need of haemodialysis. Key words: End-stage renal disease, cardiovascular disease, erythropoietin, haemodialysis. Introduction Despite a rapid improvement in dialysis technology during the last 20 years, morbidity and mortality rates remain quite high for patients of ESRD 1. Cardiovascular disease remains the major cause of mortality in ESRD and hs-crp has been the strongest predictor of cardiovascular and all cause mortality in these patients 2. Since protein and calorie malnutrition occurs commonly in these patients, therefore serum albumin concentration has been widely used as the best clinical marker of malnutrition and has been touted to be the most concerning link between malnutrition and mortality. It has been documented that the level of inflammation as assessed by major acute phase proteins like hs-crp was the most powerful factor in predicting serum albumin levels 3. Inflammation and acute phase response also interact with the haematopoetic system at several levels resulting in reduced erythropoiesis, accelerated destruction of erythrocytes and blunting of the reactive increase in erythropoietin in response to reduced haemoglobin levels 4. Therefore much interest has been focused on inflammation, the secret killer in ESRD that promotes atherosclerosis, malnutrition, and anaemia in this group of patients. Factors responsible for augmented inflammatory response in ESRD include accumulation of proinflammatory compounds, decreased clearance of cytokines, atherosclerosis per se, unrecognised persistent infections, and the dialysis procedure per se. The new clinical meaning of hs-crp in ESRD patients is that of an index that reflects their overall health state as determined by several conditions. It shows the grade of their health aggravation mainly by renal insufficiency and its complications. The accurate assessment of hs-crp gives us an estimation of the overall health status during the period of the measurement 5. A high value indicates an unfavourable condition aggravated by renal insufficiency and its complications, while a lower one should show a * Senior Professor and Head, ** Professor, *** Assistant Professor, **** Senior Resident, Department of Medicine and Nephrology, ***** Professor of Biochemistry, Pt. B.D. Sharma Post-graduate Institute of Medical Sciences, Rohtak , Haryana.
2 relatively good condition of their health 6. The significance of hs-crp levels in ESRD patients has not been studied extensively 7. The aim of the present study is to analyse the evolution of a pre-dialysis population according to their basal levels of hs-crp. Material and methods A total of 40 pre-dialysis adult patients of chronic renal failure with creatinine clearance in the range of 4-20 ml/min were included. A pre-informed consent was obtained. Patients suffering from acute or chronic infections, previous coronary vascular disease, pancreatitis, rheumatoid arthritis, inflammatory bowel disease, ankylosing spondylitis, psoriasis, or patients of burns, trauma, or who had undergone a recent surgery were excluded. The cohort of patient was followed for 6 months after initial measurement of hs-crp levels. Cutoff level of 0.6 mg/dl was used as an indicator of high levels of hs-crp 8. Patients were divided into two groups, depending upon their hs-crp levels at baseline being higher or lower than 0.6 mg/dl. All patients were prescribed diet containing approximately 0.6 gm/kg/day of protein and erythropoietin was prescribed for haemoglobin level below g/dl. hs-crp concentrations were determined using latex-enhanced immunonephelometric assays 7. During the study, patients were evaluated two monthly. On each visit, patients were examined and investigated thoroughly and findings were recorded. The data obtained during follow-up was compared between low and high hs-crp groups and its prognostic significance was analysed. Results The mean age of patients was ± years. There were 22 men and 18 women. 30% of patients were suffering from chronic glomerulonephritis, followed by hypertensive nephropathy (22.5%), obstructive uropathy (17.5%), diabetic nephropathy (15%), ischaemic nephropathy (7.5%), adult polycystic kidney disease (5%), and renal amyloidosis (2.5%). The average baseline CRP was 2.06 ± 1.82 mg/dl. 40% patients had an elevated level of hs-crp while 60% patients had hs-crp value below 0.6 mg/dl. On comparing the 2 groups haemoglobin levels were found to be significantly higher (p < 0.001) in low hs-crp group both at baseline as well as after 6 months (Table I, Fig. 1). Patients with elevated hs-crp levels had lower haemoglobin and they continued to be more anaemic on follow-up. Response to erythropoietin was also blunted in patients with high hs-crp levels (group II). The values of erythropoietin/haemoglobin ratio at baseline as well as after six months of therapy in group I patients were 0.56 ± 0.10 and 0.44 ± 0.07 respectively while in group II patients the values were 0.62 ± 0.13 and 0.53 ± Though at baseline, the difference was not significant, it was significantly higher in group II at the end of 6 months (p < 0.05) (Table I, Fig. 1). The incidence of cardiovascular events was increased in patients with high values of hs-crp. It was noticed in this study that 50% of the patients in group II had cardiovascular disease during the study period of 6 months. This was significantly different as compared to group I where only 2 patients had ischaemic episodes (p < 0.01) (Table I). Serum albumin levels were not significantly different at baseline in the two groups (p > 0.05). But at the end of the study, group I had significantly higher albumin than group II, (p < 0.001). Similarly, body mass index was also significantly higher in patients having low hs-crp at the end of the study (p < 0.05) (Table I, Fig. 1). Parameters Time in months BMI (Group 1) BMI (Group 2) Hb (Group 1) Hb (Group 2) S. Alb (Group 1) S. Alb (Group 2) Epo/Hb (Group 1) Epo/Hb (Group 2) Fig. 1: Evolution of haemoglobin, serum albumin, body mass index, and erythropoietin response in the two groups. Journal, Indian Academy of Clinical Medicine Vol. 10, No. 1 & 2 January-June,
3 The clinical course of patients with high hs-crp levels was poorer as they required early and repeated admissions for haemodialysis. In this study, no patient with low hs- CRP level required dialysis, whereas 88.75% of patients in high hs-crp (group II) required haemodialysis during the six months of study (p < 0.001). include impaired renal clearance of cytokines, accumulation of advanced glycation end-products (AGEs), atherosclerosis per se, other inflammatory diseases and unrecognised persistent infections. In addition, the dialysis procedure per se has been linked to an increased risk of inflammation 10. Table I: Evolution of haemoglobin, erythropoietin response, serum albumin, body mass index, and cardiovascular events in the two groups. Parameter Group I P value Group II P value P value (Paired t-test) (Paired t-test) (Unpaired t-test) Haemoglobin (g%) A 7.35 ± 1.41 < ± 1.22 > 0.05 > 0.05 B 9.22 ± ± 1.07 < EPO/Hb ratio A 0.56 ± 0.10 < ± 0.13 > 0.05 > 0.05 B 0.44 ± ± 0.16 < 0.05 Serum albumin (g %) A 3.25 ± 0.38 < ± 0.96 < 0.05 > 0.05 B 4.01 ± ± 0.25 < Body mass index (kg/m 2 ) A ± 2.6 < ± 3.18 > 0.05 > 0.05 B ± ± 3.26 < 0.05 Cardiovascular morbidity (%) A 0 > < 0.05 > 0.05 A = Baseline; B = After 6 months B < 0.01 Thus, the observations made in this study show that a substantial number of patients of ESRD had elevated levels of hs-crp. High levels of hs-crp were associated with poor clinical outcome in these patients due to interplay of a number of mechanisms including low haemoglobin, hypo-responsiveness to erythropoietin therapy, poor nutritional status, low albumin levels, greatly increased risk of cardiovascular disease and frequent and early need of haemodialysis. Discussion Despite improvement in dialysis technology over the past decade, mortality and morbidity in ESRD remains high 1. Recent evidence points to chronic inflammation as a major contributor to this mortality and morbidity 2. Traditional risk factors alone cannot explain the unacceptable high prevalence and incidence of cardiovascular disease in this population. Inflammation and other non-traditional risk factors are likely to contribute 9. Several factors have been implicated as potential causes of inflammation. These Among the several inflammatory biomarkers used to assess inflammation, hs-crp has attracted the most interest 11. hs-crp is 5-10-folds higher in haemodialysis patients than in healthy controls, and is multifactorial in origin 12. It has been a prominent product of the inflammatory response syndrome and a marker of overall and cardiovascular mortality in the general population and in ESRD patients 2. Raised levels of hs- CRP and other cytokines have been linked to anaemia leading to poor outcome in these patients 4. Proinflammatory cytokines and hs-crp are an important cause of lack of response to recombinant human erythropoietin therapy. The process of inflammation evidenced by elevated hs-crp levels also causes loss of muscle mass and changes in plasma composition leading to poor nutritional outcomes in ESRD population 13. In view of the increasing interest in the role of hs-crp as the most important marker of inflammation, this study was planned to see its prognostic significance in the patients of ESRD. 20 Journal, Indian Academy of Clinical Medicine Vol. 10, No. 1 & 2 January-June, 2009
4 The haemopoietic response to inflammation includes anaemia secondary to reduced erythropoiesis 4. This has been attributed to the inhibition of erythropoietin secretion by pro-inflammatory cytokines 14. Inflammation can also induce a functional iron deficiency, as cytokines can inhibit the delivery of iron from the reticuloendothelial cells to haemopoietic cells 15. Also, patients with high hs-crp levels showed poorer response to erythropoietin therapy meaning that the patients had low rise in haemoglobin (Hb) for same doses of EPO. It has been reported that the dose of EPO required for maintaining a certain Hb level in dialysis patients may be increased by 30-70% in those individuals who have high hs-crp levels as compared to those having lower values 16. The decreased survival reported in dialysis patients with markers of inflammation like hs-crp is probably related to association between inflammation and cardiovascular risk. The higher incidence of CVD in group II patients signify a strong correlation between cardiovascular disease and inflammation in ESRD 2. There are several ways in which inflammation can promote vascular injury, i.e., through alterations in lipoprotein structure and function, changes in the composition of plasma proteins, alterations in the vascular endothelium, and changes in the expression of specific ligands on the surfaces of platelets, neutrophils, and mononuclear cells 17. hs-crp levels correlated inversely with serum albumin (r = , p < 0.01). Albumin, like other nutritional markers, such as pre-albumin and transferrin, is a negative acute phase protein 18. The synthesis of these proteins decreases during inflammation, as does their serum concentrations, changes that are entirely independent of nutritional status 19. These results indicate that elevated serum markers of inflammation are associated with a poor nutritional outcome in ESRD patients resulting in increased morbidity and mortality. There was a linear relationship between hs-crp and clinical events leading to haemodialysis in this study, suggesting that inflammation influences the clinical outcome in these patients. Further, hs-crp levels were predictive of poor clinical outcome and early need for haemodialysis. The observations made in this study show that inflammation is a common feature in ESRD and is associated with an increased risk of morbidity and mortality. Raised levels of hs-crp were closely associated with poor outcomes due to interplay of a number of mechanisms including lower haemoglobin, poor response to erythropoietin on follow-up, high incidence of cardiovascular disease, poor nutritional outcomes as suggested by low serum albumin, and lower body mass index, as well as frequent and early hospitalisation for haemodialysis. Therefore, hs-crp should be included in the routine laboratory work-up for risk evaluation and stratification in ESRD. References 1. Hakim RM, Lazarus JM. Initiation of dialysis. J Am Soc Nephrol 1995; 6: Menon V, Wang X, Greene T et al. Relationship between C- reactive protein, albumin and cardiovascular disease in patients with chronic kidney disease. Am J Kidney Dis 2003; 42: Lowrie EG, Lew NL. Death risk in haemodialysis patients: The predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990; 15: Barany P. Inflammation, serum C-reactive protein and erythropoietin resistance. Nephrol Dial Transplant 2001; 16: Pepys MB, Hirschfield GM. C-reactive protein: A critical update. J Clin Invest 2003; 111: Tsirpanlis G. The pattern of inflammation and a potential new clinical meaning and usefulness of C-reactive protein in end-stage renal failure patients. Kidney Blood Press Res 2005; 28: Ortega O, Rodriguez I, Gallar P et al. Vigil significance of high C-reactive protein levels in pre-dialysis patients. Nephrol Dial Transplant 2002; 17 (6): Herzig KA, Purdie DM, Cheng W. Is C-reactive protein a useful predictor of outcome in peritoneal dialysis patients? J Am Soc Nephrol 2001; 12: Stenvinkel P, Lindholm B. C-reactive protein in end-stage renal disease: are there reasons to measure it? Blood Purif 2005; 23: Kaysen GA. Microinflammatory state in uraemia: causes and potential consequences. J Am Soc Nephrol 2001; 12: Stenvinkel P, Lindholm B. C-reactive protein in end-stage renal disease: Are there reasons to measure it? Blood Purif 2005; 23: Wanner C, Metzger T. C-reactive protein a marker for allcause and cardiovascular mortality in haemodialysis Journal, Indian Academy of Clinical Medicine Vol. 10, No. 1 & 2 January-June,
5 patients. Nephrol Dial Transplant 2002; 17 (Suppl 8): Utaka S, Avesani CM, Draibe SA et al. Inflammation is associated with increased energy expenditure in patients with chronic kidney disease. Am J Clin Nutr 2005; 82 (4): Jelkmann W. Proinflammatory cytokines lowering erythropoietin production. J Interferon Cytokine Res 1998; 18: Barany P. Inflammation, serum C-reactive protein and erythropoietin resistance. Nephrol Dial Transplant 2001; 16: Kaysen GA. Microinflammatory state in uraemia: causes and potential consequences. J Am Soc Nephrol 2001; 12: Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999; 340: Moshage HJ, Janssen JAM, Franssen JH et al. Study of the molecular mechanism of decreased liver synthesis of albumin and inflammation. J Clin Invest 1987; 79: Ritchie RF, Palomaki GE, Neveux LM et al. Reference distributions for the negative acute-phase serum proteins, albumin, transferrin and transthyretin: a practical, simple and clinically relevant approach in a large cohort. J Clin Lab Anal 1999; 13: Journal, Indian Academy of Clinical Medicine Vol. 10, No. 1 & 2 January-June, 2009
Malnutrition and inflammation in peritoneal dialysis patients
Kidney International, Vol. 64, Supplement 87 (2003), pp. S87 S91 Malnutrition and inflammation in peritoneal dialysis patients PAUL A. FEIN, NEAL MITTMAN, RAJDEEP GADH, JYOTIPRAKAS CHATTOPADHYAY, DANIEL
More informationScreening and early recognition of CKD. John Ngigi (FISN) Kidney specialist
Screening and early recognition of CKD John Ngigi (FISN) Kidney specialist screening Why? Who? When? How? Primary diagnosis for patients who start dialysis Other 10% Glomerulonephritis 13% No. of dialysis
More informationORIGINAL ARTICLE. Evaluation of Effect of Ascorbic Acid on Ferritin and Erythropoietin Resistance in Patients of Chronic Kidney Disease
32 Evaluation of Effect of Ascorbic Acid on Ferritin and Erythropoietin Resistance in Patients of Chronic Kidney Disease N Nand 1, S Venu 2, AR Deshmukh 2, R Mittal 2 ORIGINAL ARTICLE Abstract This study
More informationEnd stage renal disease and Protein Energy wasting
End stage renal disease and Protein Energy wasting Dr Goh Heong Keong MBBS,MRCP(UK) www.passpaces.com/kidney.htm Introduction Chronic kidney disease- increasing health burden in many countries. The estimated
More information1. Reggie J. Divina, M.D. (1) 2. Fe S. Felicilda, M.D., DPBCN (1,2) 3. Rufino E. Chan, M.D. (1) 4. Luisito O. Llido, M.D.
82 TITLE: Nutritional status of hemodialysis patients in the Philippines: a cross sectional survey in four out- patient dialysis centers Submitted: January 10, 2010 Posted: August 30, 2010 AUTHOR(S) 1.
More informationPrevalence of anemia and cardiovascular diseases in chronic kidney disease patients: a single tertiary care centre study
International Journal of Advances in Medicine Sathyan S et al. Int J Adv Med. 2017 Feb;4(1):247-251 http://www.ijmedicine.com pissn 2349-3925 eissn 2349-3933 Original Research Article DOI: http://dx.doi.org/10.18203/2349-3933.ijam20170120
More informationLeft ventricular hypertrophy: why does it happen?
Nephrol Dial Transplant (2003) 18 [Suppl 8]: viii2 viii6 DOI: 10.1093/ndt/gfg1083 Left ventricular hypertrophy: why does it happen? Gerard M. London Department of Nephrology and Dialysis, Manhes Hospital,
More informationTrial to Reduce. Aranesp* Therapy. Cardiovascular Events with
Trial to Reduce Cardiovascular Events with Aranesp* Therapy John J.V. McMurray, Hajime Uno, Petr Jarolim, Akshay S. Desai, Dick de Zeeuw, Kai-Uwe Eckardt, Peter Ivanovich, Andrew S. Levey, Eldrin F. Lewis,
More informationIntradialytic Parenteral Nutrition in Hemodialysis Patients. Hamdy Amin, Pharm.D., MBA, BCNSP Riyadh, Saudi Arabia
Intradialytic Parenteral Nutrition in Hemodialysis Patients Hamdy Amin, Pharm.D., MBA, BCNSP Riyadh, Saudi Arabia Disclosure Information Intradialytic Parenteral Nutrition in Hemodialysis Patients Hamdy
More informationComment on European Renal Best Practice Position Statement on Anaemia Management in Chronic Kidney Disease.
Comment on European Renal Best Practice Position Statement on Anaemia Management in Chronic Kidney Disease. Goldsmith D, Blackman A, Gabbay F, June 2013 Kidney Disease: Improving Global Outcomes (KDIGO)
More informationOnce-weekly darbepoetin alfa is as effective as three-times weekly epoetin
Artigo Original ONCE-WEEKLY DARBEPOETIN ALFA IS AS EFFECTIVE AS THREE-TIMES WEEKLY EPOETIN Rev Port Nefrol Hipert 2004; 18 (1): 33-40 Once-weekly darbepoetin alfa is as effective as three-times weekly
More informationPART ONE. Peritoneal Kinetics and Anatomy
PART ONE Peritoneal Kinetics and Anatomy Advances in Peritoneal Dialysis, Vol. 22, 2006 Paul A. Fein, Irfan Fazil, Muhammad A. Rafiq, Teresa Schloth, Betty Matza, Jyotiprakas Chattopadhyay, Morrell M.
More informationImpact of elevated C-reactive protein levels on erythropoiesisstimulating agent (ESA) dose and responsiveness in hemodialysis patients
NDT Advance Access published October 7, 2008 Nephrol Dial Transplant (2008) 1 of 7 doi: 10.1093/ndt/gfn543 Original Article Impact of elevated C-reactive protein levels on erythropoiesisstimulating agent
More informationImpact of pre-transplant anaemia correction and erythropoietin resistance on long-term graft survival
Nephrol Dial Transplant (2005) 20 [Suppl 8]: viii8 viii12 doi:10.1093/ndt/gfh1110 Impact of pre-transplant anaemia correction and erythropoietin resistance on long-term graft survival Mariarosaria Campise
More informationResearch Journal of Pharmaceutical, Biological and Chemical Sciences
Research Journal of Pharmaceutical, Biological and Chemical Sciences Study of Improvement in Quality of Life with Recombinant Erythropoietin in Chronic End Stage Renal Failure Patients. Ratna Palit 1 *,
More informationINFLUENCE OF LOW PROTEIN DIET IN IMPROVING ANEMIA TREATED WITH ERYTHROPOETIN
INFLUENCE OF LOW PROTEIN DIET IN IMPROVING ANEMIA TREATED WITH ERYTHROPOETIN, Idrizi A, Barbullushi M, Gjyzari A, Duraku A Department of Nephrology, University Hospital Center, Tirana, Albania Introduction
More informationmorbidity & mortality
morbidity & mortality esrd introduction of ESRD treatment. We examine these concerns throughout the ADR, particularly in Chapter One. This year we focus on infectious complications, especially those related
More informationMalnutrition in advanced CKD
Malnutrition in advanced CKD Malnutrition Lack of proper nutrition, caused by not having enough to eat, not eating enough of the right things or being unable to use the food that one does eat Jessica Stevenson
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Other criteria for starting dialysis GUIDELINES
Date written: September 2004 Final submission: February 2005 Other criteria for starting dialysis GUIDELINES No recommendations possible based on Level I or II evidence SUGGESTIONS FOR CLINICAL CARE (Suggestions
More informationMorbidity & Mortality from Chronic Kidney Disease
Morbidity & Mortality from Chronic Kidney Disease Dr. Lam Man-Fai ( 林萬斐醫生 ) Honorary Clinical Assistant Professor MBBS, MRCP, FHKCP, FHKAM, PDipID (HK), FRCP (Edin, Glasg) Hong Kong Renal Registry Report
More informationObjectives. Pre-dialysis CKD: The Problem. Pre-dialysis CKD: The Problem. Objectives
The Role of the Primary Physician and the Nephrologist in the Management of Chronic Kidney Disease () By Brian Young, M.D. Assistant Clinical Professor of Medicine David Geffen School of Medicine at UCLA
More informationPublished Online 2013 July 24. Research Article
Nephro-Urology Monthly. 2013 September; 5(4):913-7. Published Online 2013 July 24. DOI: 10.5812/numonthly.12038 Research Article Comparative Study of Intravenous Iron Versus Intravenous Ascorbic Acid for
More informationC-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease
Kidney International, Vol. 68 (2005), pp. 766 772 C-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease VANDANA MENON, TOM GREENE, XUELEI WANG,
More informationThe Effects of Intravenous Vitamin C Administration on hs-crp and Tumor Necrosis Factor-α Levels in Haemodialysis Patients
Functional Foods in Health and Disease 2011, 1(8):255-261 Page 255 of 261 Research Open Access The Effects of Intravenous Vitamin C Administration on hs-crp and Tumor Necrosis Factor-α Levels in Haemodialysis
More informationThe efficacy of intravenous darbepoetin alfa administered once every 2 weeks in chronic kidney disease patients on haemodialysis
Nephrol Dial Transplant (2006) 21: 2846 2850 doi:10.1093/ndt/gfl387 Advance Access publication 5 August 2006 Original Article The efficacy of intravenous darbepoetin alfa administered once every 2 weeks
More informationHepatitis B vaccination in Haemodialysis Patients: The Impact of Local Endemicity
1 Hepatitis B vaccination in Haemodialysis Patients: The Impact of Local Endemicity Dr. Salwa Ibrahim, MD MRCP Assistant Professor of Nephrology Cairo University, Egypt Patients on hemodialysis therapy
More informationTREAT THE KIDNEY TO SAVE THE HEART. Leanna Tyshler, MD Chronic Kidney Disease Medical Advisor Northwest Kidney Centers February 2 nd, 2009
TREAT THE KIDNEY TO SAVE THE HEART Leanna Tyshler, MD Chronic Kidney Disease Medical Advisor Northwest Kidney Centers February 2 nd, 2009 1 ESRD Prevalent Rates in 1996 per million population December
More informationANEMIA & HEMODIALYSIS
ANEMIA & HEMODIALYSIS The anemia of CKD is, in most patients, normocytic and normochromic, and is due primarily to reduced production of erythropoietin by the kidney and to shortened red cell survival.
More informationReceived: 19 Feb. 2011; Received in revised form: 26 Nov. 2011; Accepted: 11 Jan. 2012
ORIGINAL REPORT Significance of Albumin and C-Reactive Protein Variations in 300 End Stage Renal Disease Patients in Tehran University of Medical Sciences Hospitals During Year 2010 Nasrin Dashti 1, Nahid
More informationCurrent situation and future of renal anemia treatment. FRANCESCO LOCATELLI
Antalya May 20, 2010 12 National Congress of Turkish Society of Hypertension and Renal Disease Current situation and future of renal anemia treatment. FRANCESCO LOCATELLI Department of Nephrology, Dialysis
More informationCOMPARISON OF HIGHLY SENSITIVE CRP AND SERUM CREATININE AS AN EARLY MARKER OF RENAL IMPAIRMENT
J MEDICINE 2006; 7 : 10-14 COMPARISON OF HIGHLY SENSITIVE CRP AND SERUM CREATININE AS AN EARLY MARKER OF RENAL IMPAIRMENT ROKSANA YEASMIN 1, MD. NIZAMUL HOQUE BHUIYAN 2, SULTANA PARVEEN 1 SHAMIM ARA FERDOUS
More informationPreoperative Serum Bicarbonate Levels Predict Acute Kidney Iinjry after Cardiac Surgery
International Journal of ChemTech Research CODEN (USA): IJCRGG, ISSN: 0974-4290, ISSN(Online):2455-9555 Vol.11 No.06, pp 203-208, 2018 Preoperative Serum Bicarbonate Levels Predict Acute Kidney Iinjry
More informationmediators might be causal in the accelerated
Elevated Serum Macrophage Migration Inhibitory Factor (MIF) Concentrations in Chronic Kidney Disease (CKD) Are Associated with Markers of Oxidative Stress and Endothelial Activation Annette Bruchfeld,
More informationAnaemia in the ICU: Is there an alternative to using blood transfusion?
Anaemia in the ICU: Is there an alternative to using blood transfusion? Tim Walsh Professor of Critical Care, Edinburgh University World Health Organisation grading of the severity of anaemia Grade of
More informationSerum Hepcidin in Haemodialysis Patients: Associations with Iron Status and Microinflammation
The Journal of International Medical Research 2011; 39: 1961 1967 Serum Hepcidin in Haemodialysis Patients: Associations with Iron Status and Microinflammation Y XU, XQ DING, JZ ZOU, ZH LIU, SH JIANG AND
More informationPublished trials point to a detrimental relationship
ANEMIA, CHRONIC KIDNEY DISEASE, AND CARDIOVASCULAR DISEASE: THE CLINICAL TRIALS Steven Fishbane, MD* ABSTRACT Clinical trials have shown a strong detrimental relationship among anemia, chronic kidney disease
More informationAnemia of Chronic Disease
J KMA Special Issue Anemia of Chronic Disease Chul Soo Kim, MD Department of Internal Medicine, Inha University College of Medicine Email : cskimmd@inha.ac.kr J Korean Med Assoc 2006; 49(10): 920-6 Abstract
More informationPRE-dialysis survey on anaemia management
Nephrol Dial Transplant (2003) 18: 89 100 Original Article PRE-dialysis survey on anaemia management Fernando Valderrábano 1,y, Walter H. Hörl 2, Iain C. Macdougall 3,Jérôme Rossert 4, Boleslaw Rutkowski
More informationCardiovascular Pharmacotherapy in Special Population: Cardio-Nephrology
49 th Annual Scientific Meeting The Heart Association of Thailand under the Royal Patronage of H.M. the King Cardiology on the move 24-25 March 2017 @Sheraton, HuaHin Cardiovascular Pharmacotherapy in
More informationDesigned to be taken at facility only 3 times per week. Greater convenience for patients & caregivers and compliance for providers
MV-ONE PLUS is a novel antioxidative nutraceutical especially formulated for patients with chronic kidney disease (CKD). MV-ONE PLUS has been designed as a supplement to address vitamin D deficiency and
More informationInflammation in Renal Disease
Inflammation in Renal Disease Donald G. Vidt, MD Inflammation is a component of the major modifiable risk factors in renal disease. Elevated high-sensitivity C-reactive protein (hs-crp) levels have been
More informationPrevalence and severity of anemia in pediatric hemodialysis patients, a single center study
Received:16.7.2006 Accepted: 6.12.2006 Short Communication Prevalence and severity of anemia in pediatric hemodialysis patients, a single center study Afshin Azhir*, Jafar Nasiri**, Alaleh Gheisari* Abstract
More informationCardiovascular disease profile
Cardiovascular disease profile Kidney disease Background This chapter of the Cardiovascular disease profiles focuses on kidney disease and is produced by the National Cardiovascular Intelligence Network
More informationCAD in Chronic Kidney Disease. Kuang-Te Wang
CAD in Chronic Kidney Disease Kuang-Te Wang InIntroduction What I am going to talk about: CKD and its clinical impact on CAD Diagnosis of CAD in CKD PCI / Revasc Outcomes in CKD CKD PCI CAD Ohtake T,
More informationIndian J. Prev. Soc. Med. Vol. 45 No. 1-2, 2014
ISSN- 0301-1216 Indian J. Prev. Soc. Med. Vol. 45 No. 1-2, 2014 ANAEMIA IN CHRONIC KIDNEY DISEASE PATIENTS AND ITS RELATION TO GFR AND SOCIO-DEMOGRAPHIC PROFILE Richa Mishra 1, RG Singh 2, CP Mishra 3,
More informationAnalysis of spectrum of chronic kidney disease in IPD and OPD
FOOD SCIENCE RESEARCHPAPER RESEARCH JOURNAL e ISSN-2230-9403 Visit us : www.researchjournal.co.in Volume 6 Issue 2 October, 2015 246-250 DOI : 10.15740/HAS/FSRJ/6.2/246-250 Analysis of spectrum of chronic
More informationPeritoneal Dialysis Adequacy: Not Just Small- Solute Clearance
Advances in Peritoneal Dialysis, Vol. 24, 2008 Rajesh Yalavarthy, Isaac Teitelbaum Peritoneal Dialysis Adequacy: Not Just Small- Solute Clearance Two indices of small-solute clearance, Kt/V urea and creatinine
More information1/20/2013 CASE SOFTWARE & BOOKS REASSESSMENT OF ACUTE PHASE PROTEINS AS MARKERS OF MALNUTRITION POINTS TO PONDER FACTS ABOUT SERUM ALBUMIN
CASE SOFTWARE & BOOKS REASSESSMENT OF ACUTE PHASE PROTEINS AS MARKERS OF MALNUTRITION All rights reserved. No part of this presentation may be reproduced by any graphic, mechanical, photographic or electronic
More informationCardiovascular Complications Of Chronic Kidney Disease. Dr Atir Khan Consultant Physician Diabetes & Endocrinology West Wales Hospital, Carmarthen
Cardiovascular Complications Of Chronic Kidney Disease Dr Atir Khan Consultant Physician Diabetes & Endocrinology West Wales Hospital, Carmarthen Markers of kidney dysfunction Raised Albumin / Creatinine
More informationEfficacy and tolerability of oral Sucrosomial Iron in CKD patients with anemia. Ioannis Griveas, MD, PhD
Efficacy and tolerability of oral Sucrosomial Iron in CKD patients with anemia Ioannis Griveas, MD, PhD Anaemia is a state in which the quality and/or quantity of circulating red blood cells are below
More informationThe Diabetes Kidney Disease Connection Missouri Foundation for Health February 26, 2009
The Diabetes Kidney Disease Connection Missouri Foundation for Health February 26, 2009 Teresa Northcutt, RN BSN Primaris Program Manager, Prevention - CKD MO-09-01-CKD This material was prepared by Primaris,
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Serum phosphate GUIDELINES
Date written: August 2005 Final submission: October 2005 Author: Carmel Hawley Serum phosphate GUIDELINES No recommendations possible based on Level I or II evidence SUGGESTIONS FOR CLINICAL CARE (Suggestions
More informationThe hypertensive kidney and its Management
The hypertensive kidney and its Management Dr H0 Chung Ping Hypertension Management Seminar 20061124 Hypertensive kidney Kidney damage asymptomatic till late stage Viscous cycle to augment renal damage
More informationDr A Pokrajac MD MSc MRCP Consultant
Dr A Pokrajac MD MSc MRCP Consultant Onset at 5-15 years of T1DM Can be present at diagnosis of T2DM Detect in regular MA/Cr screening (2X first urine sample, no UTI, no other causes) Contributing Factors
More informationVascular calcification in stage 5 Chronic Kidney Disease patients on dialysis
Vascular calcification in stage 5 Chronic Kidney Disease patients on dialysis Seoung Woo Lee Div. Of Nephrology and Hypertension, Dept. of Internal Medicine, Inha Unv. College of Medicine, Inchon, Korea
More informationAssociation between serum ferritin and measures of inflammation, nutrition and iron in haemodialysis patients
Nephrol Dial Transplant (2004) 19: 141 149 DOI: 10.1093/ndt/gfg493 Original Article Association between serum ferritin and measures of inflammation, nutrition and iron in haemodialysis patients Kamyar
More informationPossible discrepancy of HbA1c values and its assessment among patients with chronic renal failure, hemodialysis and other diseases
Clin Exp Nephrol (2015) 19:1179 1183 DOI 10.1007/s10157-015-1110-6 ORIGINAL ARTICLE Possible discrepancy of HbA1c values and its assessment among patients with chronic renal failure, hemodialysis and other
More informationROYAL WOLVERHAMPTON HOSPITALS NHS TRUST
ROYAL WOLVERHAMPTON HOSPITALS NHS TRUST SHARED CARE PROTOCOL FOR ERYTHROPOIETIN USE 2016 New Cross Hospital Dr J Odum Dr P B Rylance Dr P Carmichael Dr S Acton Dr B Ramakrishna Walsall Manor Hospital Dr
More informationOptions in Renal Replacement Therapy: When, whom, which? Prof Dr. Serhan Tuğlular Marmara University Medical School Division of Nephrology
Options in Renal Replacement Therapy: When, whom, which? Prof Dr. Serhan Tuğlular Marmara University Medical School Division of Nephrology CKD Classification Stage Description GFR (ml/min/1.73.m2) 1 Kidney
More information17 th Annual Meeting of JSHDF, Sept 3-4, 2011
17 th Annual Meeting of JSHDF, Sept 3-4, 2011 Sug Kyun Shin 1, JY Moon 2, SW Han 3, DH Yang 4, SH Lee 2, HC Park 5, JK Kim 6 and YI Jo 7 1 Nephrology, NHIC Ilsan Hospital, 2 Kyunghee University Hospital
More informationIron deficiency in heart failure
Iron deficiency in heart failure Piotr Ponikowski, MD, PhD, FESC Department of Heart Diseases, Wroclaw Medical University Centre for Heart Diseases, Military Hospital, Wroclaw, Poland Objectives Importance
More informationApplying clinical guidelines treating and managing CKD
Applying clinical guidelines treating and managing CKD Develop patient treatment plan according to level of severity. Source: Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012
More informationISN Mission: Advancing the diagnosis, treatment and prevention of kidney diseases in the developing and developed world
ISN Mission: Advancing the diagnosis, treatment and prevention of kidney diseases in the developing and developed world Nutrition in Kidney Disease: How to Apply Guidelines to Clinical Practice? T. Alp
More informationIrish Practice Nurses Association Annual Conference Tullamore Court Hotel OCTOBER 6 th 2012
Irish Practice Nurses Association Annual Conference Tullamore Court Hotel OCTOBER 6 th 2012 Susan McKenna Renal Clinical Nurse Specialist Cavan General Hospital Renal patient population ACUTE RENAL FAILURE
More informationEffects of Kidney Disease on Cardiovascular Morbidity and Mortality
Effects of Kidney Disease on Cardiovascular Morbidity and Mortality Joachim H. Ix, MD, MAS Assistant Professor in Residence Division of Nephrology University of California San Diego, and Veterans Affairs
More informationInternational Journal of Current Research in Chemistry and Pharmaceutical Sciences Volume 1 Issue: Pages: 20-28
International Journal of Current Research in Chemistry and Pharmaceutical Sciences www.ijcrcps.com Volume 1 Issue: 3 2014 Pages: 20-28 (p-issn: 2348-5213; e-issn: 2348-5221) REVIEW ARTICLE PREVALENCE OF
More informationAn Audit of Poor Response To Erythropoeitin Therapy. September 1998
1 An Audit of Poor Response To Erythropoeitin Therapy September 1998 Prepared By: Nicola Austerberry Renal Audit Facilitator Phil Kalra Consultant Nephrologist 2 1 Introduction The topic for this audit
More informationChapter IV. Patient Characteristics at the Start of ESRD: Data from the HCFA Medical Evidence Form
Annual Data Report Patient Characteristics from HCFA Medical Evidence Form Chapter IV Patient Characteristics at the Start of ESRD: Data from the HCFA Medical Evidence Form Key Words: Medical Evidence
More informationADVANCES. Annual reports from the Centers for. In Anemia Management. Anemia Management in the United States: Is There Opportunity for Improvement?
ADVANCES Vol. 1 No.1 22 We are pleased to introduce our newest NPA publication, Advances in Anemia Management. This quarterly publication will address contemporary issues relating to the treatment of anemia
More informationTHE PROGNOSIS OF PATIENTS WITH CHRONIC KIDNEY DISEASE AND DIABETES MELLITUS
214 ILEX PUBLISHING HOUSE, Bucharest, Roumania http://www.jrdiabet.ro Rom J Diabetes Nutr Metab Dis. 21(3):23-212 doi: 1.2478/rjdnmd-214-25 THE PROGNOSIS OF PATIENTS WITH CHRONIC KIDNEY DISEASE AND DIABETES
More informationPrevalence of malnutrition in dialysis
ESPEN Congress Cannes 2003 Organised by the Israel Society for Clinical Nutrition Education and Clinical Practice Programme Session: Nutrition and the Kidney Malnutrition and Haemodialysis Doctor Noël
More informationPharmacological Management of Complications of End Stage Renal Disease in Patients on Maintenance Hemodialysis.
Indian Journal of Pharmacy Practice Association of Pharmaceutical Teachers of India Pharmacological Management of Complications of End Stage Renal Disease in Patients on Maintenance Hemodialysis. 1 1 Justin
More informationJMSCR Vol. 03 Issue 07 Page July 2015
www.jmscr.igmpublication.org Impact Factor 3.79 ISSN (e)-2347-176x Inflammation and Its Association with Appetite and Quality of Life of Patients on Maintenance Hemodialysis Authors N. Vanitha Rani* 1,
More informationEfficacy of Folic Acid in Anemia Treatment Among Hemodialysis Patients in Jakarta, Indonesia
Research Article Efficacy of Folic Acid in Anemia Treatment Among Hemodialysis Patients in Jakarta, Indonesia Diana Laila Ramatillah* 1, Syed Azhar Syed Sulaiman 1, Amer Hayat Khan 1, Ong Loke Meng 2,
More informationModern Medical Laboratory Journal - ISSN X
Original Article Mod Med Lab. 2017; 1(1): 17-17 22 Modern Medical Laboratory Journal - ISSN 2371-770X An Investigation of the Relationship between Beta-2 Microglobulin (β2m) and Inflammatory Factors (Serum
More informationMETHODS RESULTS. Patients
ORIGINAL ARTICLE Korean J Intern Med 2014;29:489-497 Ferritin as a predictor of decline in residual renal function in peritoneal dialysis patients Soon Mi Hur, Hye Young Ju, Moo Yong Park, Soo Jeong Choi,
More informationGeriatric Nephrology. Murtener Tage
Geriatric Nephrology Murtener Tage 2014 Isabelle.Binet@kssg.ch www.nierenstiftung.ch Plan Geriatric nephrology The elderly with CKD The elderly on dialysis The elderly in transplantation Plan Geriatric
More informationKIDNEY DIALYSIS FOUNDATION ANNUAL REPORT MEDICAL (P.D.)
KIDNEY DIALYSIS FOUNDATION ANNUAL REPORT MEDICAL (P.D.) 2005 Prepared by Dr Grace Lee Medical Director With input from: Theresa Soh Manager, Patient Services Wu Sin Yan Charge Nurse TABLE OF CONTENTS 1.
More informationTitle:Hyperphosphatemia as an Independent Risk Factor of Coronary Artery Calcification Progression in Peritoneal Dialysis Patients
Author's response to reviews Title:Hyperphosphatemia as an Independent Risk Factor of Coronary Artery Calcification Progression in Peritoneal Dialysis Patients Authors: Da Shang (sdshangda@163.com) Qionghong
More informationFigure 1 LVH: Allowed Cost by Claim Volume (Data generated from a Populytics analysis).
Chronic Kidney Disease (CKD): The New Silent Killer Nelson Kopyt D.O. Chief of Nephrology, LVH Valley Kidney Specialists For the past several decades, the health care needs of Americans have shifted from
More informationKIDNEY DIALYSIS FOUNDATION ANNUAL REPORT PERITONEAL DIALYSIS PROGRAMME
KIDNEY DIALYSIS FOUNDATION ANNUAL REPORT PERITONEAL DIALYSIS PROGRAMME 2011 Prepared by Dr Grace Medical Director With input from: Lay Kwee Chin Senior Nurse Clinician, Patient Services Theresa Soh Clinical
More informationRecombinant human erythropoietin (EPO) is an effective
Septicemia in Patients with ESRD Is Associated with Decreased Hematocrit and Increased Use of Erythropoietin Allen R. Nissenson,* Michelle L. Dylan, Robert I. Griffiths, Hsing-Ting Yu, and Robert W. Dubois
More informationComparison of Erythropoietin and Darbepoetin in Chronic Kidney Disease Patients in a Tertiary Care Hospital
Human Journals Research Article July 2017 Vol.:9, Issue: 4 All rights are reserved by Pournami A S et al. Comparison of Erythropoietin and Darbepoetin in Chronic Kidney Disease Patients in a Tertiary Care
More informationImpact of Renal Dysfunction on the Outcome of Acute Myocardial Infarction
ORIGINAL ARTICLE JIACM 2010; 11(4): 277-81 Impact of Renal Dysfunction on the Outcome of Acute Myocardial Infarction Shagun Sachdeva*, NP Singh**, Renuka Saha*** Abstract The presence of coexisting conditions
More informationExcess mortality due to interaction between proteinenergy wasting, inflammation and cardiovascular disease in chronic dialysis patients
7 Excess mortality due to interaction between proteinenergy wasting, inflammation and cardiovascular disease in chronic dialysis patients R. de Mutsert D.C. Grootendorst J. Axelsson E.W. Boeschoten R.T.
More informationAgroup of clinicians, researchers, ... REPORT... Chronic Kidney Disease: Stating the Managed Care Case for Early Treatment
... REPORT... Chronic Kidney Disease: Stating the Managed Care Case for Early Treatment Discussion and Consensus of Presentations of Economic Analyses, Managed Care Organization Case Studies, and Opportunities
More informationPatterns of medication use in the RRI-CKD study: focus on medications with cardiovascular effects
Nephrol Dial Transplant (2005) 20: 1110 1115 doi:10.1093/ndt/gfh771 Advance Access publication 15 March 2005 Original Article Patterns of medication use in the RRI-CKD study: focus on medications with
More informationMORRELL MICHAEL AVRAM, DANIEL BLAUSTEIN, PAUL A. FEIN, NAVEEN GOEL, JYOTIPRAKAS CHATTOPADHYAY, and NEAL MITTMAN
Kidney International, Vol. 64, Supplement 87 (2003), pp. S6 S11 Hemoglobin predicts long-term survival in dialysis patients: A 15-year single-center longitudinal study and a correlation trend between prealbumin
More informationBiochemical Analysis of End Stage Renal Disease Patients Following Regular Haemodialysis
Original Research Biochemical Analysis of End Stage Renal Disease Patients Following Regular Haemodialysis Ipsita Dash 1,*, Suchitra Kumari 2 1 Tutor, 2 Assistant Professor, Dept. of Biochemistry, All
More informationPlasma proteins Quantitatively, proteins are the most important part of the soluble components of the blood plasma.
Plasma proteins 42 Plasma proteins Quantitatively, proteins are the most important part of the soluble components of the blood plasma. concentrations of between 60 and 80 g L 1, they constitute approximately
More informationCardiovascular Risk Reduction in Kidney Transplant Recipients
Cardiovascular Risk Reduction in Kidney Transplant Recipients Rainer Oberbauer R.O. AUG 2010 CV Mortality in ESRD compared to the general population R.O.2/32 Modified from Foley et al. AJKD 32 (suppl3):
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Biochemical Targets. Calcium GUIDELINES
Date written: August 2005 Final submission: October 2005 Author: Carmel Hawley Biochemical Targets CARMEL HAWLEY (Woolloongabba, Queensland) GRAHAME ELDER (Westmead, New South Wales) Calcium GUIDELINES
More informationREVIEW ARTICLE NEWER BIOMARKERS IN EARLY DIABETIC NEPHROPATHY
JCD REVIEW ARTICLE NEWER BIOMARKERS IN EARLY DIABETIC NEPHROPATHY SAPTARSHI MUKHOPADHYAY* *FACULTY (DEPARTMENT OF MEDICINE), B R SINGH HOSPITAL (EASTERN RAILWAY), KOLKATA. INTRODUCTION renal disease. It
More informationRisk Factors in the Progression of Chronic Kidney Disease
Risk Factors in the Progression of Chronic Kidney Disease a report by Rainer Düsing Professor, Faculty of Medicine, University of Bonn DOI:10.17925/EE.2006.00.02.1e Chronic kidney disease (CKD) is a complex,
More informationDisease Pathogenesis and Research Progression of Renal Anemia
2018 3rd International Conference on Life Sciences, Medicine, and Health (ICLSMH 2018) Disease Pathogenesis and Research Progression of Renal Anemia Yingying Liu, Qi Jiang* Department of Nephrology, China-Japan
More informationPublished trials point to a detrimental relationship
ANEMIA, CHRONIC KIDNEY DISEASE, AND CARDIOVASCULAR DISEASE: THE CLINICAL TRIALS Steven Fishbane, MD* ABSTRACT Clinical trials have shown a strong detrimental relationship among anemia, chronic kidney disease
More informationDefining risk factors associated with renal and cognitive dysfunction Joosten, Johanna Maria Helena
University of Groningen Defining risk factors associated with renal and cognitive dysfunction Joosten, Johanna Maria Helena IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's
More informationJMSCR Vol 07 Issue 01 Page January 2019
www.jmscr.igmpublication.org Impact Factor (SJIF): 6.379 Index Copernicus Value: 79.54 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v7i1.66 Lipid Profile in Different Stages
More informationC-reactive protein: a marker or a player?
C-reactive protein: a marker or a player? Thomas Nyström, Thomas Nyström To cite this version: Thomas Nyström, Thomas Nyström. C-reactive protein: a marker or a player?. Clinical Science, Portland Press,
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Blood urea sampling methods GUIDELINES
Date written: November 2004 Final submission: July 2005 Blood urea sampling methods GUIDELINES No recommendations possible based on Level I or II evidence SUGGESTIONS FOR CLINICAL CARE (Suggestions are
More information